NCT04917744Completed
Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors
Longitudinal Metabolite Levels in Patients Receiving Maintenance PARP Inhibitors
Source: ClinicalTrials.gov · Last updated 3 Apr 2025
Brief summary (registry, in English)
This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients scheduled to receive immunotherapy for their ovarian cancer. The information gained from this study may help researchers better understand the side effects from each treatment and possibly lessen those side effects for future treatments.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 5 (actual)
- First submitted
- 2 Jun 2021
- Start date
- 1 Apr 2021
- Primary completion date
- 17 Apr 2023
- Lead sponsor
- Mayo Clinic
- Diseases
- Ovarian cancer, Childhood cancers
- NCT number
- NCT04917744
What you commit to
- Study type: Observational
- Participants enrolled: 5
- From 1 Apr 2021 to the primary completion date, 17 Apr 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients unwilling to return for blood draws, patients unwilling to continue PARP inhibitor treatment for at least one month
Who the study is looking for
- Adults
- Patients with ovarian cancer starting PARP inhibitor treatment
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.